Top hospitals aren’t offering Alzheimer's drug Aduhelm
https://www.statnews.com/2022/01/06/top-hospitals-arent-offering-aduhelm/
Almost no one is prescribing Aduhelm, Biogen's controversial new Alzheimer’s treatment that roiled the health care landscape when regulators approved it last summer. Major health care systems such as the Cleveland Clinic made it clear almost immediately that they wouldn’t offer the new therapy, citing a lack of convincing evidence that the drug actually helps treat Alzheimer’s. Now, STAT has identified another 15 university-affiliated hospitals that aren’t offering the drug, including Johns Hopkins, UCLA, and the University of Michigan. The organization that negotiates supply contracts on behalf of more than 90% of the nation’s academic hospitals estimates their members are ordering just one to five vials of the medicine each day.
“Is anyone buying it? Yes, people are. But it is so, so small that it’s almost negligible,” Steven Lucio, the senior principal of pharmacy solutions at the organization, Vizient, told STAT's Nicholas Florko. STAT+ subscribers can read more here.
https://www.statnews.com/2022/01/06/top-hospitals-arent-offering-aduhelm/
Almost no one is prescribing Aduhelm, Biogen's controversial new Alzheimer’s treatment that roiled the health care landscape when regulators approved it last summer. Major health care systems such as the Cleveland Clinic made it clear almost immediately that they wouldn’t offer the new therapy, citing a lack of convincing evidence that the drug actually helps treat Alzheimer’s. Now, STAT has identified another 15 university-affiliated hospitals that aren’t offering the drug, including Johns Hopkins, UCLA, and the University of Michigan. The organization that negotiates supply contracts on behalf of more than 90% of the nation’s academic hospitals estimates their members are ordering just one to five vials of the medicine each day.
“Is anyone buying it? Yes, people are. But it is so, so small that it’s almost negligible,” Steven Lucio, the senior principal of pharmacy solutions at the organization, Vizient, told STAT's Nicholas Florko. STAT+ subscribers can read more here.